New heart drug aims to tame deadly rhythm disorder
NCT ID NCT07277582
Summary
This study is testing a new drug called THRV-1268 to see if it can safely shorten a dangerous heart rhythm interval in people with Long QT Syndrome Type 2. About 64 participants will take the drug at different doses for several weeks while doctors closely monitor their heart's electrical activity. The goal is to find a dose that reduces the risk of life-threatening irregular heartbeats and fainting spells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG QT SYNDROME (LQTS) 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Heart Center Clinical Research Program | MGH
RECRUITINGBoston, Massachusetts, 02114, United States
-
Honor Health Research and Innovation Institute
RECRUITINGScottsdale, Arizona, 85258, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
-
University of Illinois Chicago
NOT_YET_RECRUITINGChicago, Illinois, 60612, United States
-
Wilmington Health
RECRUITINGWilmington, North Carolina, 28401, United States
Conditions
Explore the condition pages connected to this study.